Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A particular
drug used inchemotherapy .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word irinotecan.
Examples
-
In mid-May 2011, Enzon announced plans to halt the development of PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal cancer (mCRC).
unknown title 2011
-
-- July 2008 (EU): license was updated for the treatment of patients with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type mCRC in combination with chemotherapy and as a single agent in patients who have failed oxaliplatin-and irinotecan-based therapy and who are intolerant to irinotecan.
TradingMarkets 2010
-
These include alkylating agents, particularly temozolomide (Temodar), topoisomerase I poisons (irinotecan [Camptosar], topotecan [Hycamtin]), and cross-linking drugs (platinum, mitomycin C [Mitozytrex, Mutamycin]).
MedPageToday.com - medical news plus CME for physicians 2010
-
Typically, patients who fail 5-FU, oxaliplatin, irinotecan, and bevacizumab-containing therapies, and who have wild-type KRAS status receive EGFR monoclonal antibody therapy with either cetuximab or panitumumab.
Medindia Health News 2010
-
These include alkylating agents, particularly temozolomide (Temodar), topoisomerase I poisons (irinotecan [Camptosar], topotecan [Hycamtin]), and cross-linking drugs (platinum, mitomycin C [Mitozytrex, Mutamycin]).
-
-- July 2008 (EU): license was updated for the treatment of patients with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type mCRC in combination with chemotherapy and as a single agent in patients who have failed oxaliplatin-and irinotecan-based therapy and who are intolerant to irinotecan.
TradingMarkets 2010
-
PEG-SN38 or EZN-2208 is Enzon's PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).
-
-- July 2008 (Japan): for use in combination with irinotecan in patients with EGFR-expressing mCRC who have failed prior irinotecan therapy
TradingMarkets 2010
-
-- July 2008 (Japan): for use in combination with irinotecan in patients with EGFR-expressing mCRC who have failed prior irinotecan therapy
TradingMarkets 2010
-
Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.